In addition, ICOS antibody KY1044, anti-GITR antibody TRX518, anti-VEGFR2 antibody ramucirumab (RAM), and chemotherapy drugs, such as low-dose cyclophosphamide, cyclosporine A, and tacrolimus, all can reduce Tregs in tumor patients (131, 134–136), while anti-OX40 antibody produced anti-tumor activity by blocking the inhibitory effect of Tregs (137). Here, TNFRSF4 is linked to neoplasm.